9 results on '"Cuttler L"'
Search Results
2. Developmental regulation of pituitary growth hormone-releasing hormone receptor gene expression in the rat.
- Author
-
Korytko, A I, primary, Zeitler, P, additional, and Cuttler, L, additional
- Published
- 1996
- Full Text
- View/download PDF
3. Calcium signalling in single growth hormone-releasing factor-responsive pituitary cells.
- Author
-
Cuttler, L, primary, Glaum, S R, additional, Collins, B A, additional, and Miller, R J, additional
- Published
- 1992
- Full Text
- View/download PDF
4. Biphasic action of forskolin on growth hormone and prolactin secretion by rat anterior pituitary cells in vitro.
- Author
-
Szabo M, Staib NE, Collins BJ, and Cuttler L
- Subjects
- 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester pharmacology, Adenylate Cyclase Toxin, Adenylyl Cyclases metabolism, Animals, Calcimycin pharmacology, Cells, Cultured, Cholera Toxin pharmacology, Colforsin administration & dosage, Cyclic AMP biosynthesis, Dinoprostone pharmacology, Dose-Response Relationship, Drug, Drug Synergism, Enzyme Activation drug effects, Female, Growth Hormone-Releasing Hormone pharmacology, Male, Pituitary Gland, Anterior drug effects, Rats, Rats, Inbred Strains, Somatostatin pharmacology, Virulence Factors, Bordetella pharmacology, Colforsin pharmacology, Growth Hormone metabolism, Pituitary Gland, Anterior metabolism, Prolactin metabolism
- Abstract
To assess the role of cAMP-mediated signal transduction processes in mediation of secretagogue-stimulated GH release, we examined the dose-related effects of the diterpene adenylate cyclase activator forskolin (FSK) in primary monolayer cultures of rat adenohypophyseal cells. In cell cultures prepared from both immature (12 days old) and adult (6 weeks to 4 months old) male or female rats, the dose-related stimulation of GH release by FSK was biphasic. With increasing FSK concentrations from 0.03-3.16 microM, GH release increased progressively to maximal values of 442 +/- 19% and 303 +/- 10% of basal release in cells from immature and adult rats, respectively. FSK concentrations above 3.16 microM induced progressively diminished GH responses, with net inhibition to below basal release evident at 100 microM FSK. FSK stimulated PRL release to a lesser degree than it did GH release; the PRL response to FSK was also biphasic. When maximal stimulatory concentrations (Emax) of FSK and GH-releasing factor (GRF; 10 nM) were added in combination, the GH response was significantly less than the individual response to either secretagogue alone. In response to FSK alone, GRF alone, and FSK plus GRF, GH release was 478 +/- 7%, 583 +/- 11%, and 244 +/- 5%; 278 +/- 4%, 283 +/- 3%, and 175 +/- 2%; and 299 +/- 12%, 351 +/- 5%, and 191 +/- 17% of basal release in cells from 12-day-old, adult male, and adult female rats, respectively (P less than 0.01 for all responses to combined addition vs. the individual responses). Submaximal stimulatory concentrations of GRF added in combination with submaximal FSK elicited partially additive GH responses; the GH response to Emax GRF, on the other hand, was inhibited in a dose-related manner by all concentrations of FSK that by themselves were stimulatory. The GH responses were also suppressed when Emax FSK was added to cultured cells of 12-day-old rats in combination with Emax cholera toxin (2.5 ng/ml) or prostaglandin E2 (10 microM), agents whose actions, like that of GRF, involve adenylate cyclase activation. In contrast, FSK did not suppress but in most cases augmented the maximal GH responses to secretagogues whose action is independent of adenylate cyclase activation: (Bu)2cAMP (0.5 mM), TRH (100 nM), phorbol myristate acetate (50 nM), the Ca2+ ionophore A23187 (250 microM), and the dihydropyridine Ca2+ channel agonist BAY K8644 (10 microM). Indeed, combined addition of FSK with the latter two agents resulted in synergistic stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1990
- Full Text
- View/download PDF
5. Hormone ontogeny in the ovine fetus. XVIII. The effect of an opioid antagonist on luteinizing hormone secretion.
- Author
-
Cuttler L, Egli CA, Styne DM, Kaplan SL, and Grumbach MM
- Subjects
- Animals, Endorphins physiology, Female, Fetus drug effects, Gestational Age, Luteinizing Hormone blood, Morphine pharmacology, Naloxone pharmacology, Pregnancy, Sheep, Fetus metabolism, Luteinizing Hormone metabolism, Narcotic Antagonists pharmacology
- Abstract
Endogenous opioid-like peptides influence gonadotropin release in adult animals and man; however, the role of these peptides in the regulation of fetal LH secretion is not known. We administered naloxone hydrochloride (1.3 mg/kg iv), a specific opioid receptor antagonist, to 22 chronically catheterized ovine fetuses of gestational ages 94-143 days (term = 147 days). As a control, each fetus also received the vehicle on a separate occasion, the sequence of the studies being randomized. After the administration of naloxone, LH secretion increased from 38.6 +/- 5.8 to 114 +/- 21 ng/h ml-1 (P less than 0.001); LH release was not affected by administration of the vehicle. Morphine (13 mg/kg) and naloxone (1.3 mg/kg) were administered together to three fetuses (gestational age 94-105 days); LH secretion was sharply reduced from 411 +/- 14.3 ng/h ml-1 after naloxone alone to 53 +/- 17.5 ng/h ml-1 after the administration of both naloxone and morphine (P less than 0.01). The response to naloxone varied with gestational age. Fetuses of 94-115 days showed a significantly higher increment in LH secretion when given naloxone (112.3 +/- 30.7 ng/h ml-1) than did older fetuses of gestational age 126-143 days (64.8 +/- 20.8 ng/h ml-1) (P less than 0.02). These findings indicate that, in the ovine fetus endogenous opioid-like peptides exert a tonic suppressive effect on LH secretion at least as early as 94 days gestation. Moreover, the effectiveness of naloxone in augmenting LH release decreases with advancing gestational age. This latter observation supports the concept that, in the ovine fetus, endogenous opioid tone is not the sole factor involved in the dampened fetal LH secretion which is characteristic of late gestation.
- Published
- 1985
- Full Text
- View/download PDF
6. The effect of age on prostaglandin E2 stimulation of growth hormone release from cultured rat pituitary cells.
- Author
-
Cuttler L, Birkenbach PA, and Szabo M
- Subjects
- Animals, Cells, Cultured, Female, Kinetics, Male, Pituitary Gland drug effects, Pituitary Gland metabolism, Rats, Rats, Inbred Strains, Dinoprostone pharmacology, Growth Hormone metabolism, Pituitary Gland growth & development
- Abstract
Prostaglandin E2 (PGE2) is a potent secretagogue of GH in mature mammals. Although PGs are produced by the fetus and newborn of many species, the ontogeny of PGE2's GH stimulatory effect and the interaction of PGE2 with GHRF in the developing animal are not known. We examined the effects of 0.01-10 microM PGE2 and 0.01-10 nM rat GHRF, alone and in combination, on GH release from cultured pituitary cells of 2-day(d)-old, 7-d-old, 15-d-old, and adult (3- to 4-month-old) male rats (n = 4-7 experiments/age group). The effect of PGE2 on GH release was markedly age dependent. The GH response to all doses of PGE2 over 0.01 microM was greatest in pituitary cells of adult and 15-d-old rats and least in those of 2-d-old pups. PGE2 (0.1 microM) did not cause significant GH release from pituitary cells of 2-d-old pups (110 +/- 3% of control values), but increased that from 7-d-old, 15-d-old, and adult pituitary cells to 126 +/- 8%, 155 +/- 8%, and 156 +/- 9% of respective control values (by analysis of variance: F = 7.28; P less than 0.001). PGE2 (1 microM) increased GH release to 123 +/- 8%, 145 +/- 12%, 259 +/- 24%, and 260 +/- 17% of control values from pituitary cells of these same respective age groups (F = 12.3; P less than 0.001). The highest dose of PGE2 studied (10 microM) yielded similar results. The influence of PGE1 on GH release was also age dependent and similar to that of PGE2. In contrast to PGE2, GHRF stimulated GH release most in pituitary cells of 2-d-old pups and least in those of adults, similar to our previous observations with human GHRF-40. Coincubation with PGE2 and low dose GHRF resulted in partial additivity of GH response in adult rats, but no additivity in newborn pups. These results indicate that in rats, the sensitivity of the somatotroph to PGE2 increases with advancing age after birth. The contrasting developmental patterns of somatotroph sensitivity to PGE2 and GHRF support the concept that these GH secretagogues act, at least in part, by different intracellular mechanisms, which are subject to differential rates of maturation.
- Published
- 1989
- Full Text
- View/download PDF
7. Ontogeny of the in vitro growth hormone stimulatory effect of thyrotropin-releasing hormone in the rat.
- Author
-
Welsh JB, Cuttler L, and Szabo M
- Subjects
- Animals, Bucladesine pharmacology, Calcium Channel Blockers pharmacology, Cobalt pharmacology, Dose-Response Relationship, Drug, Female, Growth Hormone-Releasing Hormone pharmacology, Male, Peptide Fragments pharmacology, Pregnancy, Rats, Rats, Inbred Strains, Thyroid Gland embryology, Growth Hormone pharmacology, Thyroid Gland growth & development, Thyrotropin-Releasing Hormone metabolism
- Abstract
The ontogenic changes in the somatotroph's responsiveness to TRH were examined in enzymatically dissociated rat pituitary cells in primary monolayer culture. Exposure to TRH (10(-8) M) caused a significant increase in GH release in cultured pituitary cells from rats ranging in age from -1 day (20 days of gestational age) to 90 days. The magnitude of the response, expressed as a percent increment above control rat GH (rGH) release, rose progressively until it reached a maximum of 209 +/- 5% (mean +/- SE) on postnatal day 12. Thereafter, the response declined to values ranging from 10-30% above control rGH release. In cultured adenohypophyseal cells of rats on postnatal day 12, the effect of TRH was dose related; the effective concentration range was 10(-10)-10(-7) M, with an EC50 of 2.5 +/- 0.6 X 10(-9) M. TRH (10(-8) M) potentiated the GH stimulatory effect of a submaximally effective concentration of human GH-releasing factor-40 (hGRF-40; 10(-9) M) in cultured pituitary cells of developing rats, aged -1 to 30 days, and that of (Bu)2cAMP (5 X 10(-4) M) in cultured pituitary cells of rats aged -1 to 45 days. The rGH response to the combined addition of TRH with either hGRF-40 or (Bu)2cAMP was up to 2 times greater (P less than 0.05) than the sum of the individual responses. When the interaction of TRH (10(-8) M) with multiple concentrations of hGRF-40 (10(-10), 10(-9), and 10(-8) M) was tested in cultured pituitary cells of 4- to 36-day-old rats at 4-day intervals, synergism was least at the lowest and greatest at the highest concentration of hGRF-40; synergistic interaction decreased progressively after 20 days of age to undetectable levels by 36 days. In cultured anterior pituitary cells of 12-day-old rats, maximally stimulatory TRH (10(-7) M) potentiated the GH stimulatory effects of both hGRF-40 and (Bu)2cAMP at concentrations at the EC50 value or greater, with synergism being most pronounced at maximally effective concentrations. Whereas the GH response to the combined addition of maximal hGRF-40 (10(-7) M) and (Bu)2cAMP (1.5 X 10(-3) M) was not greater than that to maximal hGRF alone, TRH potentiated the responses to both secretagogues whether added separately or combined.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1986
- Full Text
- View/download PDF
8. The effect of age on somatostatin suppression of basal, growth hormone (GH)-releasing factor-stimulated, and dibutyryl adenosine 3',5'-monophosphate-stimulated GH release from rat pituitary cells in monolayer culture.
- Author
-
Cuttler L, Welsh JB, and Szabo M
- Subjects
- Age Factors, Animals, Bucladesine pharmacology, Cells, Cultured, Female, Growth Hormone-Releasing Hormone pharmacology, Male, Peptide Fragments pharmacology, Pituitary Gland, Anterior drug effects, Rats, Rats, Inbred Strains, Secretory Rate drug effects, Bucladesine antagonists & inhibitors, Growth Hormone metabolism, Growth Hormone-Releasing Hormone antagonists & inhibitors, Peptide Fragments antagonists & inhibitors, Pituitary Gland, Anterior metabolism, Somatostatin pharmacology
- Abstract
To test the hypothesis that relative resistance of the somatotroph to somatostatin (SRIF) contributes to elevated circulating levels of GH in the newborn rat, we examined the effects of SRIF (0.1, 0.33, and 1 nM) on basal, human pancreatic GH-releasing factor-40 (hpGRF-40; 1 nM)-stimulated, and (Bu)2cAMP (0.5 mM)-stimulated GH release from pituitary cells of 2-day-old, 15-day-old, and adult Sprague-Dawley rats in monolayer culture. The effect of SRIF on basal GH release varied markedly with age. SRIF, in the doses studied, did not inhibit basal GH release (nanograms of GH per 10(5) cells/3 h) from pituitary cultures of 2-day-old rats. In those of 15-day-old rats, only the two higher doses of SRIF (0.33 and 1 nM) suppressed GH release. By contrast, in pituitary cell cultures of adult male and female rats, all doses of SRIF significantly inhibited basal GH release (P less than 0.001). Similarly, the degree of SRIF suppression of both hpGRF-40- and (Bu)2cAMP-stimulated GH release differed among the age groups. In pituitary cultures of 2-day-old rats, SRIF did not significantly inhibit stimulated GH release. In 15-day-old rat pituitary cells, SRIF inhibited GH release, but did not eradicate the stimulatory effect of hpGRF-40 or (Bu)2cAMP. By contrast, in pituitary cell cultures of adult male and female rats, SRIF completely abolished the stimulatory effect of both hpGRF-40 and (Bu)2cAMP. When expressed as a percentage of the control (or stimulated) value, GH release at each SRIF dose varied markedly with age (P less than 0.001). Furthermore, a similar age-associated trend was evident when, in a separate series of experiments (n = 37), we examined the suppressive effect of a single concentration of SRIF (0.33 nM) on (Bu)2cAMP (0.5 mM)-stimulated GH release in cultured pituitary cells of rats ranging in age from -1 (day 20 of gestation) to 78 days. The degree of suppression increased progressively with advancing age; GH release decreased from 82 +/- 2% (+/- SE) of stimulated values in cultured cells of perinatal rats to 20 +/- 1% of stimulated values in cultured cells of 78-day-old rats. There was a significant negative correlation between age and SRIF-inhibited GH release (r = -0.89; P less than 0.001).(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1986
- Full Text
- View/download PDF
9. Differential responsiveness of the somatotroph to growth hormone-releasing factor during early neonatal development in the rat.
- Author
-
Szabo M and Cuttler L
- Subjects
- Aging, Animals, Bucladesine pharmacology, Cells, Cultured, Dose-Response Relationship, Drug, Male, Pituitary Gland drug effects, Rats, Rats, Inbred Strains, Animals, Newborn metabolism, Growth Hormone metabolism, Growth Hormone-Releasing Hormone pharmacology, Peptide Fragments pharmacology, Pituitary Gland metabolism
- Abstract
The effects of human pancreatic GH-releasing factor-40 (hpGRF-40; 0.01-100 nM) and (Bu)2cAMP (0.015-1.5 mM) on GH release from primary monolayer cultures of pituitary cells were evaluated in rats of three age groups: postnatal days 2 and 12, and young adult males (3-4 months). Both hpGRF-40 and (Bu)2cAMP elicited a dose-related increase in GH release in cell cultures from each age group. However, the magnitude of the fractional increase over basal release was markedly age dependent. hpGRF-40-stimulated GH release (expressed as a percentage of control values) was greater in cultured cells of 2-day-old than of 12-day-old rats, which was, in turn, significantly greater than in cells of adult rats (P less than 0.001). Maximum hpGRF-40-stimulated GH release was 1058 +/- 50% of control values (+/- SE) in 2-day-old, 617 +/- 21% of control values in 12-day-old, and 405 +/- 6% of control values in adult pituitary cell cultures. The slopes of the dose-response curves differed significantly among the three age groups (P less than 0.001) and varied inversely with increasing age. GH release induced by (Bu)2cAMP was similarly age dependent; maximal stimulated release was 1073 +/- 20%, 414 +/- 4%, and 259 +/- 7% of control values in cultured cells of 2-day-old, 12-day-old, and adult rats, respectively (P less than 0.001 for age effect at each dose). As with hpGRF-40, the slopes of the dose-response curves for (Bu)2cAMP decreased with advancing age (P less than 0.001). Intracellular GH storage during culture, basal release of GH, and serum GH were also age dependent. Pooled serum GH was consistently elevated in 2-day-old rats (139 +/- 2 ng ml-1), became lower and more variable in 12-day-old rats (62 +/- 14 ng ml-1), and was even more variable in adult male rats (79 +/- 23 ng ml-1), owing to random sampling during spontaneous secretory pulses. These results indicate that the stimulatory effects of GRF and (Bu)2cAMP on GH secretion from cultured rat pituitaries vary with age; pituitary cells of newborn rats are relatively more sensitive to these secretagogues than those of adult rats. This increased responsiveness of the neonatal somatotroph to GRF may contribute to the elevation of the plasma GH concentration which is characteristic of the perinatal period in the rat.
- Published
- 1986
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.